StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$5.70−0.81 (-12.44%)

Close on Nov 17, 2026Market cap $11.10MP/E –Yield –

Akari Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Akari Therapeutics's total debt was $200.00K at Sep 30, 2024.

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024$200.00K–
Q2 FY2024Jun 30, 2024$600.00K–
Q1 FY2024Mar 31, 2024$900.00K–

More Akari Therapeutics figures

See a number that looks wrong?